Growth-hormone research peptides in Australia: GHRH analogues and GHRPs

Growth-hormone research peptides in Australia. The growth-hormone-secretagogue space is one of the more-searched corners of research peptides — and one where framing matters most. This pillar guide explains what GHRH analogues and GHRPs are, how the two receptor classes differ, why they are studied in combination, and how research-grade material is verified. It is framed strictly around receptor and pathway research: it makes no muscle, performance, anabolic, or human-use claim.

Two receptor classes: GHRH analogues and GHRPs

Growth-hormone research peptides fall into two receptor-distinct classes. GHRH analogues — such as CJC-1295 (no DAC), a stabilised GHRH(1-29) analogue also catalogued as Mod GRF (1-29) — act on the GHRH receptor. GHRPs (growth-hormone-releasing peptides) — such as Ipamorelin, a selective agonist — act on the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). The two classes are distinct but converge on the same somatotrophic-axis research model.

The research behind the compounds

Ipamorelin was introduced and characterised by Raun and colleagues (European Journal of Endocrinology, 1998) as the first selective growth-hormone secretagogue — in their research models it acted with a selectivity profile that made it the “cleanest” standalone GHRP in the literature. The receptor it agonises, GHS-R1a, was cloned and identified by Howard and colleagues (Science, 1996). On the GHRH side, the stabilising D-Ala2 substitution central to the Mod GRF (1-29) / no-DAC backbone was characterised by Soule and colleagues (The Journal of Clinical Endocrinology & Metabolism, 1994). These are studied in vitro as receptor-research tools.

Why a GHRH and a GHRP are studied together

Because the two receptor classes act at different, convergent points of the same research model, the canonical research pairing combines one GHRH analogue and one GHRP. That is the rationale behind the co-lyophilised CJC-1295 + Ipamorelin research blend — the research-stack guide covers the pairing, and the CJC-1295 GHRH guide covers the standalone GHRH (including the DAC vs no-DAC distinction).

What this category is not framed for

This is worth stating plainly. The growth-hormone-secretagogue category is framed strictly around receptor and pathway research. Elite AU Peptides makes no muscle, performance, anabolic, bodybuilding, or human-use claim about any compound in it. Where you see these compounds discussed elsewhere in a performance context, that is not how they are studied here or supplied here — they are laboratory reference compounds for receptor research.

Identity, purity and compliance

Every GH-secretagogue batch is independently HPLC-tested by Janoshik before it is listed, with the certificate published on the product page and in the lab-reports library — real batch number, measured percentage, independently verifiable at janoshik.com. Browse the full GH-secretagogue research category. Everything is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.